Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539718 | 0.96 | ADRB3 (0.61) | ADRB3ADRB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6539720 | 0.91 | ADRB3 (0.60) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6539448 | 0.90 | ADRB3 (0.58) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6539082 | 0.88 | ADRB3 (0.62) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6539550 | 0.88 | ADRB3 (0.61) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6539241 | 0.87 | ADRB3 (0.60) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6539775 | 0.86 | ADRB3 (0.59) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL6541344 | 0.85 | ADRB3 (0.58) | ADRB3ADRB1NPC1RAB9AMEN1 | |
| SCHEMBL7532289 | 0.85 | ADRB3 (0.58) | ADRB3ADRB1 | |
| SCHEMBL6539506 | 0.85 | ADRB3 (0.59) | ADRB3ADRB1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6826033-B2 | BETA 3 ADRENERGIC RECEPTOR AGONISTS; TREATMENT OF POLLAKIURIA, URINARY INCONTINENCE, OBESITY OR DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20040037022-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-02-26 | — | — | US | disclosed |